Pregled bibliografske jedinice broj: 763717
Predklinička ispitivanja inhibicijskog i interakcijskog potencijala novih lijekova na razini citokroma P450
Predklinička ispitivanja inhibicijskog i interakcijskog potencijala novih lijekova na razini citokroma P450 // Farmaceutski glasnik : glasilo Hrvatskog farmaceutskog društva, 71 (2015), 229-242 (podatak o recenziji nije dostupan, članak, stručni)
CROSBI ID: 763717 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Predklinička ispitivanja inhibicijskog i interakcijskog potencijala novih lijekova na razini citokroma P450
(Preclinical cytochrome P450 inhibition and interaction studies of new drug candidates)
Autori
Bojić, Mirza
Izvornik
Farmaceutski glasnik : glasilo Hrvatskog farmaceutskog društva (0014-8202) 71
(2015);
229-242
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, stručni
Ključne riječi
citokrom P450; inhibicije; interakcije
(cytochrome P450; inhibition; interaction)
Sažetak
Sažetak u FG se piše na engleskom jeziku. In 1998 mibefradil – an antihypertensive drug, blocker of calcium channel, was withdrawn from the marked after more than 30 clinically significant interactions with other xenobiotics were reported in less than a year on the market. As in most cases enzyme involved was from the superfamily of cytochromes P450. In this paper approach in studying cytochromes P450 and drug inhibitions in vitro is reviewed. Different types of inhibition are described: direct and time dependent inhibition, and metabolism dependent inactivation. These studies were accepted by pharmaceutical industry for the assessment of potential drug- drug interactions in early stages of drug development, and now are being formalized by regulatory bodies in Europe (2013), Japan (2014) and USA to follow.
Izvorni jezik
Hrvatski
Znanstvena područja
Farmacija
Citiraj ovu publikaciju:
Časopis indeksira:
- Scopus
Uključenost u ostale bibliografske baze podataka::
- EMBASE (Excerpta Medica)